0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Dry Eye Disease

Drug Information

Target Indication

Dry Eye Disease

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

OYST

Oyster Point Pharma, Inc.

Related Pipeline

Long Term Follow up Dry Eye Disease

Dry Eye Disease (DED)

Dry Eye Disease

Dry Eye Disease

Neurotrophic Keratopathy

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts